News
IFRX
1.360
-0.73%
-0.010
Weekly Report: what happened at IFRX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at IFRX last week (0408-0412)?
Weekly Report · 04/15 09:20
Weekly Report: what happened at IFRX last week (0401-0405)?
Weekly Report · 04/08 09:21
InflaRx N.V. Announces 2024 AGM Details
TipRanks · 04/04 20:58
Weekly Report: what happened at IFRX last week (0325-0329)?
Weekly Report · 04/01 09:21
Weekly Report: what happened at IFRX last week (0318-0322)?
Weekly Report · 03/25 09:21
Investor Optimism for InflaRx’s INF904: Assessing Potential in CSU and HS Markets
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on InflaRx (IFRX – Research Report) on March 21 and set a price target of $5.00. The company is developing an oral small molecule aimed at treating chronic spontaneous urticaria. The drug has shown promise in Phase 1 trials.
TipRanks · 03/25 01:25
LifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)
Sam Slutsky maintains a Hold rating on InflaRx (IFRX) The company’s shares opened today at $1.53. The company is a clinical-stage biopharmaceutical company. The Street suggests a Moderate Buy analyst consensus rating for Infl aRx.
TipRanks · 03/22 19:05
InflaRx Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 03/22 12:28
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
Benzinga · 03/22 12:22
Buy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904’s Market Potential
TipRanks · 03/22 10:16
InflaRx Advances Anti-Inflammatory Therapeutics
TipRanks · 03/22 01:27
IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023
InflaRx reported earnings per share of -30 cents for the fourth quarter of 2023. The company reported revenue of $2,461. This was 99.82% worse than the analyst estimate of $1.40 million. Infla Rx reported results for the last quarter of 2013.
Investorplace · 03/21 15:53
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/21 12:45
InflaRx N.V. Targets Immuno-Dermatology Growth
TipRanks · 03/21 11:57
InflaRx reports FY results
InflaRx reports FY net loss of €42.7 million, or €0.78 per common share. Cash, cash equivalents and marketable securities of €98.4 million expected to fund operations at least into 2026. Infla Rx reports results on March 21.
Seeking Alpha · 03/21 11:09
Earnings Scheduled For March 21, 2024
Creative Realities is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Welltower is likely to report earnings for its fourth quarter. Accenture is also projected to report before the bell. Other companies expected to be reporting before the Bell include Shoe Carnival, Y.M.C. And Y.T.
Benzinga · 03/21 10:15
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
InflaRx N.V. Will host a conference call on March 21, 2024 to discuss the Company's anticipated development plans for INF904. The Company will publish its financial and operating results for the fourth quarter and full year 2023 in advance of the call. InflaRx is a pioneering anti-inflammatory company.
Barchart · 03/19 06:30
Weekly Report: what happened at IFRX last week (0311-0315)?
Weekly Report · 03/18 09:21
Weekly Report: what happened at IFRX last week (0304-0308)?
Weekly Report · 03/11 09:21
More
Webull provides a variety of real-time IFRX stock news. You can receive the latest news about Inflarx through multiple platforms. This information may help you make smarter investment decisions.
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.